Kathrin Brockmann

List of Publications by Year
in descending order

74 papers	5,029 citations	159585 30 h-index	106344 65 g-index
79 all docs	79 docs citations	79 times ranked	6810 citing authors

#	Article	IF	Citations
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
2	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	9.0	374
3	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	7.6	323
4	GBAâ€associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Movement Disorders, 2015, 30, 407-411.	3.9	214
5	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
6	Gait analysis with wearables predicts conversion to Parkinson disease. Annals of Neurology, 2019, 86, 357-367.	5.3	137
7	Arm swing as a potential new prodromal marker of Parkinson's disease. Movement Disorders, 2016, 31, 1527-1534.	3.9	136
8	Penetrance estimate of LRRK2 p.G2019S mutation in individuals of nonâ€Ashkenazi Jewish ancestry. Movement Disorders, 2017, 32, 1432-1438.	3.9	126
9	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122
10	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Movement Disorders, 2013, 28, 216-219.	3.9	112
11	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. Movement Disorders, 2017, 32, 1401-1408.	3.9	91
12	Cognitive changes in prodromal Parkinson's disease: A review. Movement Disorders, 2017, 32, 1655-1666.	3.9	82
13	Poor Trail Making Test Performance Is Directly Associated with Altered Dual Task Prioritization in the Elderly â€“ Baseline Results from the TREND Study. PLoS ONE, 2011, 6, e27831.	2.5	78
14	Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinsonâ€™s disease. Brain, 2017, 140, 2444-2459.	7.6	76
15	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. Movement Disorders, 2017, 32, 1025-1034.	3.9	75
16	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
17	Clinical and brain imaging characteristics in leucineâ€rich repeat kinase 2â€“associated PD and asymptomatic mutation carriers. Movement Disorders, 2011, 26, 2335-2342.	3.9	65
18	Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. Journal of Neurology, 2018, 265, 1618-1624.	3.6	58

#	Article	IF	Citations
19	Inflammatory profile in LRRK2-associated prodromal and clinical PD. Journal of Neuroinflammation, 2016, 13, 122.	7.2	57
20	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
21	Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Neurobiology of Disease, 2013, 54, 280-288.	4.4	52
22	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinsonâ€™s disease and dementia with Lewy bodies. Acta Neuropathologica Communications, 2021, 9, 175.	5.2	49
23	<scp>Î±â€Synuclein</scp> in Plasmaâ€Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. Movement Disorders, 2021, 36, 2508-2518.	3.9	47
24	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	12.8	44
25	Insulin sensitivity predicts cognitive decline in individuals with prediabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001741.	2.8	42
26	Identification of sixteen novel candidate genes for late onset Parkinsonâ€™s disease. Molecular Neurodegeneration, 2021, 16, 35.	10.8	41
27	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. Annals of Neurology, 2021, 90, E1-E12.	5.3	41
28	GBA -associated PD. Neurology, 2012, 79, 213-220.	1.1	40
29	The Mutation Matters: <scp>CSF</scp> Profiles of <scp>GCase</scp>, Sphingolipids, Î±â€Synuclein in <scp>PD_{GBA}</scp>. Movement Disorders, 2021, 36, 1216-1228.	3.9	40
30	SNCA: Major genetic modifier of age at onset of Parkinson's disease. Movement Disorders, 2013, 28, 1217-1221.	3.9	36
31	The significance of GBA for Parkinson's disease. Journal of Inherited Metabolic Disease, 2014, 37, 643-648.	3.6	36
32	<scp>CSF NFL</scp> in a Longitudinally Assessed <scp>PD</scp> Cohort: Age Effects and Cognitive Trajectories. Movement Disorders, 2020, 35, 1138-1144.	3.9	36
33	Soluble <scp>CD163</scp> Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. Movement Disorders, 2021, 36, 963-976.	3.9	35
34	Broad clinical phenotype in Parkinsonism associated with a base pair deletion in RAB39B and additional POLG variant. Parkinsonism and Related Disorders, 2016, 31, 148-150.	2.2	32
35	Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alphaâ€Synuclein Profiles. Movement Disorders, 2020, 35, 495-499.	3.9	32
36	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	5.3	30

#	Article	IF	Citations
37	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. Neurology, 2021, 96, e399-e411.	1.1	29
38	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
39	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. Clinical Neurology and Neurosurgery, 2018, 165, 88-93.	1.4	26
40	Mild Parkinsonian Signs in the Elderly â€“ Is There an Association with PD? Crossectional Findings in 992 Individuals. PLoS ONE, 2014, 9, e92878.	2.5	25
41	Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alphaâ€synuclein profile. Movement Disorders, 2019, 34, 1069-1073.	3.9	24
42	EIF4G1is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts: Table1. Journal of Medical Genetics, 2015, 52, 37-41.	3.2	23
43	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. Movement Disorders, 2020, 35, 1233-1238.	3.9	22
44	GBA-associated PD: chances and obstacles for targeted treatment strategies. Journal of Neural Transmission, 2022, 129, 1219-1233.	2.8	22
45	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. PLoS ONE, 2015, 10, e0138863.	2.5	21
46	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	2.8	21
47	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. Parkinsonism and Related Disorders, 2015, 21, 1427-1434.	2.2	20
48	Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinsonâ€™s disease and cognition. Brain, Behavior, and Immunity, 2022, 101, 182-193.	4.1	20
49	Cognitive impairment in Glucocerebrosidase (GBA)â€associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Movement Disorders, 2017, 32, 1780-1783.	3.9	19
50	CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers. Frontiers in Neurology, 2022, 13, 834580.	2.4	17
51	Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene. Frontiers in Neurology, 2018, 9, 1094.	2.4	16
52	Arm swing asymmetry in overground walking. Scientific Reports, 2018, 8, 12803.	3.3	16
53	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	3.1	16
54	Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, S183-S200.	2.8	16

#	Article	IF	Citations
55	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. BMC Neurology, 2015, 15, 192.	1.8	15
56	Reasons for mild parkinsonian signs â€“ Which constellation may indicate neurodegeneration?. Parkinsonism and Related Disorders, 2015, 21, 126-130.	2.2	15
57	<scp>CSF</scp> Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in <scp>PD</scp> and <scp>DLB</scp>. Movement Disorders, 2021, 36, 2595-2604.	3.9	15
58	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	3.9	15
59	A Neurodegenerative Vascular Burden Index and the Impact on Cognition. Frontiers in Aging Neuroscience, 2014, 6, 161.	3.4	14
60	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. Alzheimer's Research and Therapy, 2016, 8, 42.	6.2	14
61	Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD). Neurobiology of Aging, 2018, 70, 242-246.	3.1	14
62	Parkinsonâ€™s disease: evolution of cognitive impairment and CSF AÎ²_{1â€“42} profiles in a prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 165-170.	1.9	14
63	SNPs in AÎ² clearance proteins. Neurology, 2017, 89, 2335-2340.	1.1	13
64	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for ParkinsonÂ´s disease. European Journal of Neurology, 2021, 28, 1557-1565.	3.3	12
65	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. Movement Disorders, 2018, 33, 1349-1353.	3.9	10
66	GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds. Frontiers in Cell and Developmental Biology, 2020, 8, 562522.	3.7	10
67	TCS in Monogenic Forms of Parkinsonâ€™s Disease. International Review of Neurobiology, 2010, 90, 157-164.	2.0	9
68	Clinical characteristics related to worsening of motor function assessed by the Unified Parkinsonâ€™s Disease Rating Scale in the elderly population. Journal of Neurology, 2015, 262, 451-458.	3.6	6
69	Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism. Parkinsonism and Related Disorders, 2018, 55, 145-147.	2.2	6
70	Abnormally reduced frontal cortex activity during Trail-Making-Test in prodromal parkinson's diseaseâ€“a fNIRS study. Neurobiology of Aging, 2021, 105, 148-158.	3.1	6
71	The Interaction between <scp>HLAâ€ÐRB1</scp> and Smoking in Parkinson's Disease Revisited. Movement Disorders, 2022, 37, 1929-1937.	3.9	4
72	Dual-Task Performance in GBA Parkinsonâ€™s Disease. Parkinson's Disease, 2017, 2017, 1-6.	1.1	2

#	Article	IF	Citations
73	REM sleep behaviour disorder (RBD): risk for Parkinsonism and executive dysfunction in elderly. Oncotarget, 2018, 9, 36732-36733.	1.8	2
74	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. Frontiers in Neurology, 2021, 12, 757748.	2.4	2